Simplify Asset Management Inc. Reduces Stake in Regeneron Pharmaceuticals, Inc. $REGN

Simplify Asset Management Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 65.0% during the first quarter, HoldingsChannel reports. The firm owned 10,900 shares of the biopharmaceutical company’s stock after selling 20,253 shares during the period. Regeneron Pharmaceuticals comprises approximately 0.1% of Simplify Asset Management Inc.’s portfolio, making the stock its 23rd biggest holding. Simplify Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $8,422,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. HB Wealth Management LLC boosted its holdings in Regeneron Pharmaceuticals by 41.6% in the 1st quarter. HB Wealth Management LLC now owns 3,436 shares of the biopharmaceutical company’s stock valued at $2,655,000 after purchasing an additional 1,009 shares during the period. World Investment Advisors increased its holdings in shares of Regeneron Pharmaceuticals by 5.9% in the first quarter. World Investment Advisors now owns 845 shares of the biopharmaceutical company’s stock worth $653,000 after purchasing an additional 47 shares during the period. Boyd Watterson Asset Management LLC OH raised its position in shares of Regeneron Pharmaceuticals by 1.4% in the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 15 shares in the last quarter. Turtle Creek Wealth Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 18.2% in the first quarter. Turtle Creek Wealth Advisors LLC now owns 454 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 70 shares in the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of Regeneron Pharmaceuticals by 56.2% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 30,702 shares of the biopharmaceutical company’s stock worth $23,722,000 after buying an additional 11,050 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on REGN shares. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Finally, Canaccord Genuity Group cut their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $654.27 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals, Inc. has a one year low of $532.60 and a one year high of $821.11. The business’s 50 day simple moving average is $652.48 and its two-hundred day simple moving average is $725.50. The stock has a market capitalization of $69.17 billion, a P/E ratio of 15.94, a price-to-earnings-growth ratio of 1.44 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $8.22 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.